Floatz Rating
B56/100
Confidence
Indicative
Sponsor
Hansoh BioMedical R&D Company
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07186452CT.gov Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT07035392CT.gov Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06963502CT.gov A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06703177CT.gov A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With Solid Tumors | — | Recruiting | — | — | — |
NCT06594874CT.gov A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06439589CT.gov Phase Ib/II Study of HRS2398 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06417554CT.gov A Trial of SHR-A2102 With or Without Antitumor Therapy in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06332170CT.gov ARTEMIS-101: A Study of HS-20093 Combinations in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06336707CT.gov HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06112704CT.gov HS-20093 in Patients with Advanced Esophageal Carcinoma and Other Advanced Solid Tumors | — | Recruiting | — | — | — |
Show 5 more trialsShow fewer
NCT06092268CT.gov A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05867420CT.gov A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | — | Recruiting | — | — | — |
NCT05942378CT.gov A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT05794477CT.gov A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT04716634CT.gov Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Participants With Selected Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adebrelimab (this asset) | Hansoh BioMedical R&D Company | P2 | B · 56 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Adebrelimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Colorectal Cancer | — | P4 | BB · 67 |
| Non-Small Cell Lung Carcinoma | — | P3 | BB · 66 |
| Small Cell Lung Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adebrelimab in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adebrelimab-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →